x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

Select consensus findings and recommendations
of the NCI Multiple Myeloma Steering Committee
for early relapse1*†

Two Arrows In a Circle Icon Two Arrows In a Circle Icon

*This paper summarizes discussions within the National Cancer Institute (NCI) Myeloma Steering Committee and a representative group of investigators comprising the relapsed-refractory working group. The goal was to identify gaps, challenges, and therapeutic opportunities and identify areas of research likely to lead to improvements in treatment.

These points are not all inclusive of the findings and recommendations stated in the paper.

Approved IMiD® combination therapies for your patients with RRMM

Pd Doublet Therapy DPd Triplet Therapy

DPd, POMALYST + dexamethasone + daratumumab; Pd, POMALYST + dexamethasone; RRMM, relapsed/refractory multiple myeloma.

References: 1. Kumar S, Baizer L, Callander NS, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12(6):98 doi: 10.1038/s41408-022-00695-5